Embed Size (px)
Citation preview
Daar, I.,87
Dang, C. V., 339
Author Index / Volume 1 669
Author Index / Volume 1
Abate, C., 455Abdollahi, A., 637
Abe, K., 591Agarwal, S., 483Alpen, 0., 591
Angrand, P-O., 519
Arteaga, C. L., 367Azar, C. C., 421
Azannia, R., 661
BBacker, J. M., 499Bading,H., 113
Baker, S. J., 571
Barbacid, M., 9Bascom, C. C., 241
Basilico, C., 63
Basolo, F., 407Beckwith, M., 549Belinsky, C. S., 171
Benedict, W. F., 401Bensi,C., 491
Beyer, E. C., 661Bignon, Y-J., 647
Blair, D. C., 87, 119, 217Blondel, B. J., 463Bodescot, M., 87
Bookstein, R., 17Borner, C., 653Bovi, P. D., 63Braun, L., 103
Bravo, R., 305Brodeur, C. M., 421Brugge, J. S., 661Buckley, J. D., 401Buonamassa, D. T., 491Busch, H., 319
CCallahan, R., 463Cavenee, W. K., 201Chambers, A. F., 333Chattopadhyay, B., 79Chauhan, S. S., 361Chen, J., 79, 383Chen, L. B., 53Chen, P-L., 17, 233Cheviile, A. L., 63Chin, K-V., 361Chung, A. E., 429Ciandiello, F., 407, 463Clanton, D. I., 217Clawson, C. A., 559Coffey, R. J., Jr., 367Cohen, P. S., 149Coilant, F., 447Coliant, F. R., 259Cooper,M.J., 149Cornwell, M. M., 607Craig, A. M., 333Cuadrado, A., 9Curran, T., 455
n
Daughaday, W. H., 325Deed, R., 463Denhardt, D. T., 333Dickson, C., 463Distel, R. J., 483Dombalagian, M., 3
Doneili, A., 543
Donoso, L. A., 233Dugger, T. C., 367
Dunn, K. J., 87, 119
Earp, H. S., 393Edwards, D. R., 333El-Badry, 0. M., 325Eilingsworth, L., 549
Elliott, J. W., 407Emerson, D. L., 313
Enkemann, S. A., 375
Enslen, H., 627
FFarnham, P. J., 179Fausto, N., 103
Feanon, E. R., 571Ferrari, S., 543Filson, A. J., 661Finlay, C. A., 571Flamm, S. L., 63
Fong, A. M., 271Forry-Schaudies, S., 473Freytag, S. 0., 339Friedman, E., 617Fuks, A., 209, 527Furukawa, K., 135
Gamou, S., 351
George, M. D., 535Gerondakis, S., 345Goldfarb, M., 439
Goodman, R., 483Gottesman, M. M., 57, 361Gniegel, S., 401Grippo, J. F., 535
Gnisham, J. W., 393Gruber, C. E., 473Grumont, R. J., 345Gruppuso, P., 103
Guadagno, S. N., 653Guo, X., 333Gutierrez, L., 217
HHackeng, W. H. L., 299Hafez,M.M.,617Hannis,M.O., 171
Hatem, C. L., 559Hazan, R., 3Heiman, L. J., 149, 325
Henning-Chubb, C., 259
Herrera, R., 483Hinds, P. W., 571Hitomi,J., 591Hoemann, C. D., 581Hoffman-Liebermann, B., 637
Holmes, W. E., 129Honda, S., 591
Honegger, A., 191
Honisberger, U., 299Houghton, P. J., 325
Hsiao, W-L. W., 653Hsieh, L-L., 653
Hsu, C-Y. J., 191Huang, S., 233Huberman, E., 259, 447
Hudziak, R. M., 129Hughes, S. H., 473Hurwitz, D. R., 191Hutchins,G.M., 149
Hwang, Y-W., 217Hynes, N., 407
IhIe, J. N., 87
Infante, D., 617Israel, M. A., 149Ito,Y., 135
lyer, A., 87
Jetten, A. M., 535Jhiang,S.M., 319
Johann, S. V., 119Johnson, P. F., 47Jones, P. A., 383, 401
KKailenbach, S., 519Kanazawa, K., 73Keller, J. R., 549Kern, F. C., 63Kiguchi, K., 259Kim, N., 407
Kindy, M. S., 27
Klein, C., 247
Klinger, H. P., 119
Kmiec, E. B., 39
Kmiecik, T. E., 87Kodama, S., 73
Kohn, E. C., 325Koilmar, R., 179
Konieczny, S. F., 375Kuroki, T., 511
LLamberts, S. W. J., 299Langton, B. C., 407Leach, R. J., 401Lee, E. Y-H. P., 17, 233, 429,
647
Lee, W-H., 17, 233, 429, 647
Lee, W. M. F., 339Lenormand, P., 627Levine,A.J., 571
Levitt, M. L., 311Lewis, C. D., 129Liebermann, D. A., 637Lippman, M. E., 63Liscia, D. S., 463Loewenstein, W. R., 661Longo, D. L., 549
Lord, K. A., 637
Lu,Y-Y., 217
Lucas, D. A., 535
Luk, D., 455
Lupu, R., 63Lyons, R. M., 367
MacAllan, D., 463MacLeod, C. L., 271
Magewu, A. N., 401Magun, B. E., 627Manfredini, R., 543Margolis, B., 3
Marino, P. A., 57Masui, H., 407
Matnisian, L. M., 241
Matsushima, T., 591
Matsuzawa, A., 225McBain, I. A., 281McCutchen, C. M., 367McGeady, M. L., 407Mehmet, H., 293
Mehrel,T., 161Melli,M., 491Mendelsohn,J., 407
Mendola, C. E., 499Mengod,G., 299Mennie, R. J., 149
Menlo, G. R., 463Mikkelsen, 1., 201Mikumo, R., 103
Miller, D. A., 241Minniti, C., 325Mitchell, M., 313Moeiling,K., 113
Mohammadi, M., 191Mona, M., 491Morris, C., 293Moses, H. L., 241, 367Mueller, C. C., 281Muidoon, L. L., 627Murakami, A., 225Murao, S-i., 447
Murphree, A. L., 401
Murphy, L. C., 333
NNathan, M., 191Naylor, S. L., 647
Nervi,C., 535
Nose, K., 511
0Ogawa, E., 135
Ogiso, Y., 217
O’Hara,B., 119
Ostrowski, M. C., 601Owen, R. D., 601
P_______________Palacios, J. M., 299Parfett, C. L. J., 333Park, M., 87Pastan, I., 57, 361Peters, C., 463, 503
670 Author Index / Volume 1
Pettit, G. R., 281
Qian, Y., 429Quartin, R. S., 571
Rajewsky, M. F., 401Rappolee, D., 647Raugei,G., 491Raymond, V. W., 393Reid, R. E., 333
Reubi, J. C., 299Reynolds, C. P., 421Roberts, T. M., 483
Robins,T., 119
Rodland, K. D., 627Rojas, M., 527Roncaglia, R., 543Roop, D. R., 161Ross, A. H., 79
Rossi, E., 543
Rossini, M., 491Rother,C., 401
Rousset, i-P., 519Rozengurt, E., 293
Rubinson,H., 119
Ruscetti, F. W., 549Russo,J., 407
SSaeki, T., 407
Saito, H., 511
Salomon, D. S., 407, 463
Sanders, D. A., 251Santi, M., 543Sass, P., 119Satake,M., 135Satterberg, B., 483Scavarda, N. J., 421Schiegel, R., 171
Schlessinger, J., 3, 191
Schnier, J., 647
Schwartz, A. M., 559
Schwarz,M.A., 313Seal, B. S., 271
Shepard, H. M., 129
Sherman, M. I., 535Shew, J-Y., 1 7, 647
Shigesada, K., 135Shih,T.Y.,217
Shimizu, N., 351
Shimosato, Y., 351
Shudo, K., 535Sing, C. K., 549Sipes, N. J., 241
Smith,G.H., 161Souie, H., 407
Spiegelman, B. M., 483Stanners, C. P., 209, 527
Sumegi,J., 247
Sutrave, P., 87
TTagiiafico, E., 543Takakuwa, K., 73Talbot, N., 9
Tanaka, H., 225
Tanaka, K., 73
Taparowsky, E. J., 375Testa, J. R., 97To, R. Q., 39Torelli, C., 543Toreili, U., 543
UUeda, H., 73Ullnich, A., 3, 129, 191
Urba, W. J., 549Uzvolgyi, E., 247
VValvenius, E. M., 463Vande Woude, G. F., 1, 55,
87
Venkatakrishnan, C., 79
Verma, I. M., 27
Vitek, S. M., 119
Vogeistein, B., 571
Vollbeng, T. M., 535
WWalls, L., 271Walton, K., 483Wang, N. P., 233, 429
Wang, Y-F., 559
Waterhouse, P., 333
Weinstein, I. B., 653
Weiss, M. C., 519
Welistein, A., 63
Wilkinson, M. F., 271
Winawer,S., 617
Winkler, J. K., 241
Wrathail, L. S., 217
YYahata, C., 73
Yamaguchi, K., 591
Yamaguchi, Y., 135
Yaneva,M., 319
Yokozaki, H., 407
Zarbl, H., 581
Zhou, H., 209
Zilberstein, A., 3
Zugmaier, C., 63
Cadherin
Subject Index / Volume 1 671
Subject Index / Volume 1
AAdenovirus 5 E1A
repression of muscle-specificenhancers
inhibition, myogenic regulatoryfactor genes, 375
Adhesion moleculeintercellular
biliany glycoprotein, Ca2�dependency, 527
specificity, immunoglobulmnsupengene family, 209
Adipocytesinhibition of cell differentiation
c-myc, activities and properties, 339Adrenal cortex
autocrine growth stimulation
secreted Kaposi fibrobiast growthfactor, 63
Adrenal medullachromaffin neuroblasts
arrested differentiation,neuroblastoma cell lines, 149
Albuminpromoter
gene silencing, dediffenentiatedhepatoma variants, 519
Allelespaternal
preferential retention, humanretinoblastoma, 401
suppressors of malignant phenotype,201
2-Aminopurineinduction of premature mitosis
mammalian cells, 171
AP-1-dependent gene transcription
direct role for c-los, 483
ATP-binding proteinM, 46,000 nuclear scaffold
nucleoside tniphosphatase,proteolysis and monoclonalantibodies, 559
5-Aza-2’-deoxycytidine
potentiation of MyoDi activity, 383
BBaculovirus system
expression of human netinoblastomagene product
pp1 10RB in insect cells, 429Basement membrane
reconstitutedneunite outgrowth in PC12 cells,
nerve growth factor, 313Breast neoplasms
growth stimulationanti-transforming growth factor �
antibodies, 367presence of c-erbB-2 gene product-
related proteinculture medium, 591
r
Ca2�’-dependent intercellular adhesionmolecule
biliary glycoprotein, 527
Calcium-dependent intercellular adhesion
moleculebiliary glycoprotein, 527
1 2-O-tetradecanoylphorboI-1 3-acetateand thapsigangin
distinct signaling pathways, geneexpression, 627
transcriptional down-regulationc-myc expression, human T
lymphoblastic tumor cell line, 113
Calcyclinmouse homologue
serum-inducible mRNA, 333Carcinoembryonic antigen
specificity of intercellular adhesionimmunogiobulin supergene family,
209Carcinogenesis
liver
transforming growth factor $1, 103Carcinoma
Kaposi fibrobiast growth factorautocrine growth stimulation, 63
wild-type and mutant embryonal cellsnuclear retinoic acid receptors, 535
Carcinoma, coloniccolon enterocytic differentiation
transforming growth factor �, 617
ras transformationmutant p53 DNA clones, 571
Carcinoma, small cell lungepidermal growth factor receptor gene
expression
morphological variant, 351C127 cells
resistance to transformationtyrosine protein kinase oncogenes, 9
Cell culturepresence of c-erbB-2 gene product-
related proteinbreast cancer, 591
Cell cycleexpression
human proliferation-associatednucleolar antigen p120, 319
induction of premature mitosis2-aminopunine and 6-
dimethylaminopunine, mammaliancells, 171
c-losdirect role
AP-1 -dependent gene transcription,483
expression in Swiss 3T3 cellsmultiple synergistic signal
transduction pathways, 293Chromaffin cells
adrenal medullary neurobiastsarrested differentiation,
neunoblastoma cell lines, 149Chromatin
transcniptionally activeassembly, role for topoisomerase II,
39Chromosomes
translocations in human cancer, 97
c-mycinhibition of cell differentiation
definition, activities and properties,339
transcriptional down-regulation ofexpression
protein pathways, human Tlymphoblastic tumor cell line, 113
Colonenterocytic differentiation
transforming growth factor-�9,, 617
Colonic neoplasmsactivation of proteoglycan metabolism
phorbol esters, terminaldifferentiation, 281
Connexin43tyrosine phosphorylation of gap
junction proteininhibition, cell-to-cell
communication, 661
Cyclic AMPmultiple synergistic signal transduction
pathwaysc-los expression, Swiss 3T3 cells, 293
Cytokinesimmediate early response of myeloid
leukemiaterminal differentiation, growth
inhibitory stimuli, 637
n
6-Dimethylaminopurineinduction of premature mitosis
mammalian cells, 171
DNA-binding activity
nuclear protein, c-los and c-jun, 455
-binding activity of retinoblastomaprotein
carboxyl-terminai region, 233
mutant p53 clonesras transformation, human colon
carcinomas, 571
upstream and downstream sequencesmultidnug resistance gene,
transcription, 607DNA, complementary
chicken cardiac tropomyosin
low-molecular-weight nonmuscietropomyosin, alternative splicing,473
human gene conferring sensitivity to
infection
gibbon ape leukemia virus, 119immediate early response of myeloid
leukemiaterminal differentiation, growth
inhibitory stimuli, 637
isolation of novel clonesT lymphoma cells, multiple
membrane-spanning protein, 271mouse homologue of calcyclin
serum-inducible mRNA, 333mouse met protooncogene
structure, tissue-specific expressionand transforming activity, 87
Gap jundion proteintyrosine phosphorylation
672 Subject Index / Volume I
transforming growth factor-aexpression
c-Ha-ras protooncogene, MCF-1OA
cells, 407
DNA topoisomerase IIassembly of transcniptionally active
chromatin, 39regulation of mdr RNA levels
response to cytotoxic drugs, rodentcells, 361
Embryogenesisdevelopmental expression
Xenopus Iaevis los protooncogene,27
F9 cell-specific silencerubiquitous repressor, suppression by
cell-specific factors, 135
Embryonic cellsdifferential expression
HLA-A, -B, -C locus specific genes,73
Endrofloxicinassembly of transcniptionaily active
chromatin, 39Epidermal growth fador
receptorrecombinant cytoplasmic domain,
protein tyrosine kinase activity,191
Epithelial cellsmammary
transforming growth factor-a, c-Ha-ras protooncogene, 407
Epitheliummammary
differential keratin gene expression,161
Exonsdeletion of splice donor site
unphosphoryiated RB protein,
inability to bind 5V40 antigen, 17
FF9 cells
-specific silencerubiquitous repressor, suppression by
cell-specific factors, 135Fibroblast growth fador
family, 439
Kaposi
autocrine growth stimulation, 63mouse int-2 gene, 463-responsive genes, 305
Fibrobiastsmunine c-re! transcription
mitogenic agents and TPA, 345
NIH 3T3
met protooncogene amplification,tumor necrosis factor-a, 129
v-los transformation-specific alterationsgene expression, reventant cell lines,
581
C.
inhibition, cell-to-cellcommunication, 661
GenesAP-1-dependent transcription
direct role for c-los, 483CAD
growth regulation, characterizationof5’ end, 179
distinct signaling pathways
12-O-tetradecanoylphorbol-13-acetate and thapsigargin, 627
F9 cell-specific silencer
ubiquitous repressor, suppression bycell-specific factors, 135
growth factor-responsivefibroblasts, 305
human
sensitivity to infection, gibbon apeleukemia virus, 119
immediate early response of myeloidleukemia
terminal differentiation, growthinhibitory stimuli, 637
int-2
fibrobiast growth factor activity, 463
inter!eukin l�9
control of expression, inducibleenhancer, 491
keratin
differential expression, mouse
mammary epithelium, 161
muitidrug resistanceupstream and downstream
sequences, transcription, 607
MyoDipotentiation of activity, 5-aza-2 ‘-
deoxycytidine, 383
myogenic regulatory factoradenovirus 5 E1A, repression of
muscle-specific enhancers, 375
oncogenes at viral integration sites,503
RBpp1 10RB expression in insect cells,
baculovirus system, 429suppression of tumonigenicity,
WERI-Rb-27 retinoblastoma cells,247
silencingexogenous albumin promoter,
dedifferentiated hepatomavariants, 519
suppressors of malignant phenotype,201
Genomic imprintingpreferential retention of paternal
alleleshuman retinobiastoma, 401
Glycoproteinsbiliary
intercellular adhesion molecule, Ca21’dependency, 527
c-erbB-2 gene product-related proteinbreast cancer, 591
Goblet cellscolon enterocytic differentiation
transforming growth factor �, 617Granulocytes
differentiation of HL6O cellsc-myb and c-les antisense
oligodeoxynucleotides, 543Growth fador
-responsive genes in fibrobiasts, 305GTPases
low molecular weightguide, 251
GTP bindingtrans-dominant suppressor mutations
H-ras oncogene, 217
Gutcolon enterocytic differentiation
transforming growth factor $�, 617
HHeta cells
control of expressionhuman inter!eukin l�3 gene,
inducible enhancer, 491
Hepatocytestranscriptional activators, 47
Hepatomadedifferentiated variants
exogenous albumin promoter,intertypic hybrids, 519
HER2/neuautophosphorylation sites, 3
Human leukocyte antigen complexantigen-A, -B, -C locus specific genes
differential expression, trophoblastand embryonic cells, 73
HL6O cellsgranulocytic differentiation
c-myb and c-les antisenseoligodeoxynucleotides, 543
H-rastrans-dominant suppressor mutations,
217
Immunoglobulinsbiliary glycoproteins
intercellular adhesion molecule, Ca21’dependency, 527
supergene familyspecificity, intercellular adhesion,
209IMP dehydrogenase
inhibitorsinduction of cell differentiation,
melanoma cells, 259Infection
human gene conferring sensitivitygibbon ape leukemia virus, 119
Insulin-like growth fador IIautocnine growth and motility factor
human nhabdomyosarcoma tumors,325
KKeratin
differential gene expressionmouse mammary epithelium, 161
LLamins A/C
Mr 46,000 nuclear scaffold ATP-binding protein
NTPase, proteolysis, 559
Leukemia, myeioiddissection of immediate early response
Subject Index / Volume 1 673
terminal differentiation, growth
inhibitory stimuli, 637Leukemia virus
gibbon apehuman gene conferring sensitivity to
infection, 119
Leukocytesantigen-A, -B, -C locus specific genes
differential expression, trophoblastand embryonic cells, 73
Livercarcinogenesis
transforming growth factor �1, 103
chemically transformed cell lineepidermal growth factor receptor
induction, retinoic acid, 393regenerating
regulation, multidrug resistancegene, 57
transcriptional activators inhepatocytes, 47
Lovastatinblock of N-ras-induced neuronal
differentiation, 499Lymphoma
growth inhibition of cell linetransforming growth factor fi-
mediated autocnine negative loop,phorbol mynistate acetate, 549
Malignancysuppressors of malignant phenotype,
201Mammalian cells
induction of premature mitosis2-aminopunine and 6-
dimethylaminopunine, 171
Mammary glandepithelial cells
transforming growth factor-a, c-Ha-ras protooncogene, 407
epitheliumdifferential keratin gene expression,
161Mammary neoplasms
metastatic phenotypehst gene expression, 225
MCF-1OAtransforming growth factor-a
expressionc-Ha-ras protooncogene, 407
MC3T3-E1 cellsinduction by 12-0-
tetradecanoylphorbol-1 3-acetateisolation of gene sequence, ras-
transformed cells, 511
Melanomainduction of cell differentiation
inhibitors of IMP dehydrogenase,259
Meningiomasomatostatin receptor-containing
autocnine feedback regulation,somatostatin, 299
Metastasis
hst gene expressionmouse mammary tumors, 225
Mitogenic agentsmunine c-re! transcription
induction in T-cells and fibroblasts,
345Mitosis
premature2-aminopunine and 6-
dimethyiaminopunine, induction inmammalian cells, 171
Monoclonal antibodiesM, 46,000 nuclear scaffold ATP-
binding proteinNTPase, proteolysis, 559
presence of c-erbB-2 gene product-related protein
culture medium, breast cancer, 591
Monocytic cellscontrol of expression
human inter!eukin l�9 gene,inducible enhancer, 491
Monomyelocytic cellsprotein complex expressed during
terminal differentiationinhibitor of cell growth, 447
Morphogenesisarrested differentiation
chromaffin adrenal meduilaryneuroblasts, neuroblastoma tumorcell lines, 149
Multidrug resistancegene regulation
regenerating rat liver, 57gene sequences
upstream and downstreamsequences, transcription, 607
regulation of mdr RNA levels
response to cytotoxic drugs, rodentcells, 361
Musclehuman rhabdomyosarcoma tumors
insulin-like growth factor II,
autocnine growth and motilityfactor, 325
potentiation of MyoDi activity5-aza-2’-deoxycytidine, 383
-specific enhancers repressed byadenovirus 5 E1A
inhibited expression, myogenicregulatory factor genes, 375
Mutagenesis
trans-dominant suppressor mutationsH-ras oncogene, 217
MyoDipotentiation of activity
5-aza-2’-deoxycytidine, 383
Nerve growth fador-induced differentiation of human
neuroblastomaneuroepithelioma cell lines, 79
neunite outgrowth in PC12 cellsreconstituted basement membrane,
313receptor
multiple defects, humanneurobiastoma, 421
Neuritesoutgrowth in PC12 cells
reconstituted basement membrane,nerve growth factor, 313
Neuroblastomamultiple defects
nerve growth factor receptor, 421
neuroepithelioma cell lines andnerve growth factor-induced
differentiation, 79
tumor cell linesarrested differentiation, chromaffin
adrenal meduliary neuroblasts,149
Neuronsblock of N-ras-induced differentiation
block by lovastatin, 499
NIH 3T3 cellsmouse homologue of caicyclin
serum-inducible mRNA, 333N-myc
nerve growth factor-induceddifferentiation
human neurobiastoma andneuroepithelioma cell lines, 79
Nonspecific cross-reading antigenspecificity of intercellular adhesion
immunogiobulin supergene family,209
Nuclear fadorras-responsive enhancer elements
human tumor cells, 601
Nuclear proteinstimulation of DNA-binding activity
c-los and c-jun, 455
Nucleolar antigensp120
0.
expression, proliferation, 319
Oligodeoxynucleotidesc-myb and c-fes antisense
granulocytic differentiation, HL6Ocells, 543
Oncogenes: see a!so specific typeN-ras-induced neuronai differentiation
block by lovastatin, 499ras: see a!so ras
increased protein kinase C-aexpression, 653
mutant p53 DNA clones, humancolon carcinomas, 571
tyrosine protein kinaseresistance to transformation, Cl 27
cells, 9v-los
alterations in gene expression,revertant cell lines, 581
viral integration sites, 503Oncogenesis
trans-dominant suppressor mutationsH-ras oncogene, 217
Osteoblastic cellsinduction by 12-0-
tetradecanoylphorbol-1 3-acetateisolation of gene sequence, ras-
transformed cells, 51 1
P-
p53mutant DNA clones
ras transformation, human colon
carcinomas, 571PC12 cells
neunite outgrowth
674 Subject Index / Volume 1
reconstituted basement membrane,nerve growth factor, 313
P-giycoproteinregulation of mdr RNA levels
response to cytotoxic drugs, rodent
cells, 361Phorbol esters
activation of proteoglycan metabolismterminal differentiation, colon cancer
cells, 281Phorbol myristate acetate
growth inhibition of lymphoma cellline
transforming growth factor-a, 549Polyomavirus
F9 cell-specific silencerubiquitous repressor, suppression by
cell-specific factors, 135Pregnancy
differential expression of HLA-A, -B, -Cgenes
trophoblast and embryonic cells, 73Procollagen
v-los transformation-specific alterationsgene expression, revertant cell lines,
581
Proteincomplex expressed during terminal
differentiation
inhibitor of cell growth,monomyelocytic cells, 447
synthesis pathwaysc-myc expression, human T
lymphoblastic tumor cell line, 1 13Protein disulfide isomerase
altered regulation
growth-inhibitory effects,
transforming growth factor flu , 241
Protein kinaseinhibitors 2-aminopunine and 6-
dimethylaminopunine
induction of premature mitosis,mammalian cells, 171
Protein kinase C1 2-0-tetradecanoylphorbol-1 3-acetate
and thapsigargindistinct signaling pathways, gene
expression, 627
Protein kinase C-aincreased expression
transformation by ras oncogene, 653
Protein kinase C-decreased expression
transformation by ras oncogene, 653Proteoglycan
metabolism in human colon cancercells
terminal differentiation, phorboiesters, 281
Protoo�cogenesc-los and c-jun
stimulation of DNA-binding activity,nuclear protein, 455
c-Ha-ras
transforming growth factor-a,mammary epitheiial cells, 407
c-myb and c-les antisenseoligodeoxynucleotides
granulocytic differentiation, HL6O
cells, 543c-re!
transcription induced in T-ceiis andfibroblasts, mitogenic agents andTPA, 345
metstructure, tissue-specific expression
and transforming activity, 87tumor necrosis factor a, NIH 3T3
fibroblasts, 129Xenopus !aevis los
developmental expression, 27Pyrimidine
characterization of 5’ endgrowth-regulated Syrian hamster
CAD gene, 179
ras: see a!so Oncogenes-responsive enhancer elements
nuclear factor, human tumor cells,601
-transformed cellsisolation of gene sequence induced
by TPA, mouse osteoblastic cells,511
Receptorsepidermal growth factor
autophosphorylation sites, HER2/
neu, 3
induction by retinoic acid,
transformed rat cell line, 393morphological variant, small cell lung
carcinoma, 351recombinant cytopiasmic domain,
protein tyrosine kinase activity,191
growth factorc-erbB-2 gene product-related
protein, breast cancer, 591nerve growth factor
multiple defects, humanneuroblastomas, 421
nuclear retinoic acidwild-type and mutant embryonal
carcinoma cells, 535somatostatin
autocnine feedback regulation,meningiomas, 299
transforming growth factor-flgrowth inhibition, lymphoma cell
line, 549
Retinoblastomagene product ppl 10RB
expression in insect cells,baculovirus system, 429
humanpreferential retention, paternal
alleles, 401
suppression of tumorigenicityexpression, RB gene, 247
Retinoblastoma proteinCys7#{176}�to Phe substitution
loss of binding to SV4O T antigen,647
DNA-binding activitycarboxyl-terminal region, 233
unphosphorylated
inability to bind SV4O T antigen,deletion of splice donor site, 17
Retinoic acidepidermai growth factor receptor
induction
transformed rat cell line, 393nuclear receptors
wild-type and mutant embryonalcarcinoma cells, 535
Retrovirusintegration sites
oncogenes, 503Revertant cells
alterations in gene expressionv-los, 581
Rhabdomyosarcomaautocnine growth and motility factor
insulin-like growth factor II, 325RNA
mdr levels
response to cytotoxic drugs, rodentcells, 361
RNA, messengercolon enterocytic differentiation
transforming growth factor fl�, 617deletion of splice donor site
unphosphorylated RB protein,inability to bind SV4O T antigen,
17
c
epidermal growth factor receptor geneexpression
morphological variant, small cell lungcarcinoma, 351
expressionhuman proliferation-associated
nucleolar antigen p120, 319liver carcinogenesis
transforming growth factor flu, 103regulation of multidrug resistance gene
regenerating rat liver, 57
serum-inducible
mouse homologue of caicyclin, 333
Sarcoma virustyrosine phosphorylation of gap
junction protein
inhibition, cell-to-cellcommunication, 661
Simian virus 40 T antigeninability to bind by unphosphorylated
RB proteindeletion of splice donor site, 17
loss of bindingCys7#{176}�to Phe substitution,
retinobiastoma protein, 647
Somatostatinlack of evidence for autocnine
feedback regulationsomatostatin receptor-containing
meningiomas, 299Suramin
autocnine growth stimulationsecreted Kaposi fibroblast growth
factor, 63
TT-cells
munine c-re! transcriptionmitogenic agents and TPA, 345
3T3 cellsc-los expression
multiple synergistic signaltransduction pathways, 293
12-O-Tetradecanoylphorboi-13-acetate
Subject Index! Volume 1 675
induction of mouse osteoblastic cells colon enterocytic differentiation, 61 7 nuclear factor, 601isolation of gene sequence, ras- cells resistant to growth-inhibitory solid
transformed cells, 51 1 effects chromaffin adrenal meduilarymurine c-re! transcription altered regulation, protein disuifide neurobiasts, neurobiastoma tumor
induction in T-ceils and fibroblasts, isomerase, 241 cell lines, 149345 liver carcinogenesis Tyrosine
Thapsigargin mRNA expression and growth phosphorylation of gap junction12-0-tetradecanoylphorboi-1 3-acetate effects, 1 03 protein
and Transplantation antigens inhibition, cell-to-cell
distinct signaling pathways, gene differential expression of HLA-A, -B, -C communication, 661
expression, 627 genes Tyrosine protein kinaseT lymphoblastic cells trophobiast and embryonic cells, 73 autophosphorylation sites, 3
transcriptional down-regulation Tropomyosin generation of recombinant cytoplasmic
c-myc expression, protein pathways, cardiac domain1 1 3 low-molecular-weight nonmuscie epidermal growth factor receptor,
T lymphoma cells tropomyosin, alternative splicing, 191
isolation of novel complementary DNA 473 met protooncogene amplificationclones Tumorigenicity tumor necrosis factor a, NIH 313
multiple membrane-spanning suppression of WERI-Rb-27 fibroblasts, 129
protein, 271 retinoblastoma cells oncogenesTransforming growth fador-a expression, RB gene, 247 resistance to transformation, Cl 27
enhancement in mammary epitheliai suppressors of malignant phenotype, cells, 9cells 201
c-Ha-ras protooncogene, Tumor necrosis fador a
transformation, 407 met protooncogene amplification V
Transforming growth fador-fl NIH 313 fibroblasts, 129 VM-26antibodies Tumor promoters assembly of transcriptionaiiy active
growth stimulation, human breast 1 2-0-tetradecanoyiphorboi-1 3-acetate chromatin, 39
cancer cells, 367 and thapsigargin
-mediated autocnine negative ioop distinct signaling pathways, gene
growth inhibition, lymphoma cell expression, 627 X___________________________line, 549 Tumors Xenopus Iaevis los
Transforming growth fador-fll ras-responsive enhancer elements in protooncogeneautocnine-negative growth regulator cells developmental expression, 27
Cell Growth & Differentiation i
Instructions for Authors
Scope
CELL GROWTH & DIFFERENTIATION publishes significant,original research on mechanisms governing normal and abnor-mal cell behavior. A broad range of in vitro and in vivo studiesrelating to cell growth control will be considered. Papers maybe of any length, provided they are written concisely. All sub-missions undergo peer review by experts in the field and arepublished within about ten weeks of acceptance.
In addition to original studies, the journal publishes ResearchCapsu!es, invited papers which summarize and update rapidlychanging concepts in molecular biology. The journal also fea-tunes a Viewpoints section which serves as a forum for signed oranonymous write-in discussion of studies published in CELLGROWTH & DIFFERENTIATION or in other journals. All sub-missions to the Viewpoints section will be subject to reviewprior to publication.
Editorial Policy
When a manuscript is received for consideration, the Editorsassume that no similar paper has been or will be submitted forpublication elsewhere. Further, it is understood that all authorslisted on a manuscript have agreed to its submission. Uponacceptance, authors must transfer copyright to the AmericanAssociation for Cancer Research, Inc., the publisher and copy-right owner of the journal, prior to publication.
Review Process
The review process is conducted as rapidly as possible, expe-
dited by FAX transmission and overnight mail service. Manu-scripts may be submitted directly to one of the Editors or to theEditor-in-Chief. If a paper is returned for revision prior to pub-iication, the revised version must be submitted within one
month of the provisional acceptance. It is journal policy not tosend authors the reviews of manuscripts that are unacceptable
for publication.
Manuscript Submission
Mail manuscripts directly to an appropriate member of theEditorial Board at that member’s institution. Submit three onig-inai sets (not photocopies) of illustrations along with three copiesof the manuscript. A set of illustrations will be returned to theauthor if the paper is not accepted for publication.
Enclose a covering letter specifying:
1 . that the paper should be considered for publication in CELLGROWTH & DIFFERENTIATION
2. the exact address, telephone and FAX numbers of the con-responding author
If a manuscript is closely related to papers that are in press orhave been submitted elsewhere, please provide copies of thosepapers with your submission.
Format
Manuscripts must be written succinctly in clear, grammaticalEnglish. Define abbreviations in an inclusive footnote to the text.
Double-space on 8 1/2 X 1 1-inch paper, except for theabstract which should be single-spaced. Dot-matrix printing isnot acceptable. The format is as follows:
1. Title page, including: title; authors and affiliations; completeaddress, FAX and phone numbers of the corresponding au-
thor; and an abstract of no more than 250 words single-spaced to lit on the title page;
2. A running title of fewer than 50 characters;
3. Text, arranged in this order: Introduction, Results, Discussion,Materials and Methods, Acknowledgments, References;
4. Footnotes, on a page separate from the text. Designate
footnotes consecutively with superscript Arabic numerals;
5. Tables, on pages separate from the text, with descriptive
titles and/on legends;
6. Figure legends, on pages separate from the text. Define allsymbols and include staining for halftones, where applicable.
Relerences
Include only those articles that have been published or are inpress. Unpublished data or personal communications must becited as footnotes to the text. Personal communications shouldbe substantiated by a letter of permission.
Number references in the order of their first mention in thetext. Cite only the number assigned to the reference. References
must be double-spaced.Sample references:
1 . Maniatis, T., Fnitsch, E. F., Lauer, J., and Lawn, R. M. Molecular
genetics of human hemoglobins. Annu. Rev. Genet., 14: 145-
178, 1981.
2. Davis, L. C., Dibner, M. B., and Battey, J. F. Basic Methodsin Molecular Biology, pp. 44-50. New York: Elsevier Science
Publishing Co., Inc., 1986.
Illustrations
Provide three original sets of illustrations (whether line-cut draw-ings or halftones). Label each figure in pencil on the reverse sidewith the first author’s name, figure number, and an arrowindicating top of figure. Letters and numbers on illustrationsshould not be larger than 12-point type. All illustrations will be
published at a width of 3 �/8 inches unless the author requests agreater width. Use tissue overlays to indicate important areas ofthe photographs that must be reproduced with the greatestfidelity.
Indicate magnifications by means of a bar on the photograph.Present karyotypes in the form of cardboard plates onto which
chromosome sections from an original photomicrograph arepasted. Present nucleic acid sequences as glossy prints or orig-inal typescnipts.
The complete expense of reproducing color photographs willbe charged to the author. Submit color illustrations on flexiblebacking.
Prools
Page proofs must be returned to the office of the AmericanAssociation for Cancer Research within 48 hours of receipt.
Return proofs by overnight mail. Prools not received by thedeadline will be published without the authors’ corrections.Accepted manuscripts are regarded as final copy and shouldnot be altered substantially in proof, except for correction ofprinter’s errors.
For more inlormation, contact:
Dr. George F. Vande Woude, Editor-in-Chief, ABL-Basic Re-search Program, NCI-Fredenick Cancer Research and Develop-ment Center, P. 0. Box B, Building 469, Frederick, MD 21702-1201. Telephone: (301)846-1584. FAX: (301)696-1549.
or:
Publications Department, American Association for Cancer Re-search, Public Ledger Building, Sixth and Chestnut Streets, Suite816, Philadelphia, PA 19106. Telephone: (215)440-9300. FAX:(215)440-9354.
See reverse for names and addresses of Editorial Board mem-beN.
ii Instructions for Authors
CellGrowth& Differentiation
Editorial Board
George F. Vande Woude, Ph.D.Editor-in-ChielABL-Basic Research ProgramNCI-Fredenick Cancer Research
and Development Center
P.O. Box B, Building 469Frederick, MD 21702-1201FAX: 301-696-1549
Maniano Banbacid, Ph.D.Department of Molecular BiologySquibb institute for Medical ResearchP.O. Box 4000Princeton, NJ 08543-4000FAX: 609-734-3597
Webster K. Cavenee, Ph.D.Ludwig Institute for Cancer Research
687 Pine Avenue, WestMontreal, Quebec H3A 1A1CanadaFAX: 514-288-5716
Suzanne Cony, Ph.D.Waiter and Eliza Hall instituteP.O. Royal Melbourne HospitalVictoriaAustraliaFAX: 613-347-0852
Tom Curnan, Ph.D.Department of Molecular OncologyRoche Institute of Molecular Biology340 Kingsland StreetNutley, NJFAX: 201-235-7617
Raymond L. Enikson, Ph.D.Department of Cell
and Developmental BiologyHarvard University16 Divinity AvenueCambridge, MA 02138FAX: 61 7-495-9300
Nancy A. Jenkins, Ph.D.ABL-Basic Research ProgramNC1-Fredenick Cancer Research
and Development CenterP.O. Box B, Building 539Frederick, MD 21702-1201FAX: 301-663-1273
Frank McCormick, Ph.D.
Cetus Corporation1400 53rd StreetEmeryville, CA 94608FAX: 415-658-5239
Harold L. Moses, M.D.Department of Cell BiologyVanderbilt UniversitySchool of MedicineNashville, TN 37232-2175FAX: 615-343-4539
Yasutomi Nishizuka, M.D., Ph.D.Department of BiochemistryKobe University School of MedicineKobe 650JapanFAX: 078-351-0082
Gordon G. Peters, Ph.D.Imperial Cancer Research Fund
LaboratoriesSt. Bartholomew’s Hospital59 Bartholomew CloseLondon EC1A 7BE
United KingdomFAX: 44-71-796-3907
Joseph Schlessinger, Ph.D.Department of PharmacologyNew York UniversitySchool of Medicine550 First AvenueNew York, NY 10016FAX: 212-340-7133
BENEFITS OF MEMBERSHIP
AMERICAN ASSOCIATION FOR CANCER RESEARCH
INFORMATION ON APPLICATION FOR ACTIVEAND CORRESPONDING MEMBERSHIP
The American Association for Cancer Research (AACR) is ascientific society consisting of laboratory and clinical cancerresearchers. It was founded in 1 907 “to bring together activeinvestigators of the cancer problem for presentation and discus-sion of new or significant observations; and to foster research incancer and other phenomena of growth.” Members of the AACRenjoy the following benefits:
1 . subscriptions to the journals Cancer Research and CellGrowth & Differentiation at the reduced member rate;
2. the privilege of sponsoring an abstract for presentation atthe AACR annual meeting;
3. an advance copy of the Program and Proceedings pertain-ing to each annual meeting;
4. a reduced registration rate at all scientific meetings;5. early notification of events in the AACR’s series of special
conferences;6. subscriptions to any future AACR journals at reduced
member rates;7. reduced rates for the AACR Employment Register;8. the benefit of AACR’s public education activities;9. the receipt of AACR newsletters, meeting announcements,
and an up-to-date membership directory.
QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators wholive in the Americas, and who have conducted two years ofmeritorious research that has resulted in publications relevant tocancer. If a candidate is working in a research area not directlyrelated to the cancer field but has conducted research of excep.tional scientific merit, he or she may also qualify for membership.
Corresponding membership is open to qualified persons whoare not residents of the Americas. The requirements for corre-sponding membership are the same as those for active mem-bership. Visiting scientists from outside the Americas who intendto return to their countries of origin soon after submitting theirapplications should apply for corresponding membership. Allother individuals should apply for active membership and transferto corresponding status at a later date if they should leave theAmericas.
PROCEDURES FOR APPLICATION
There are three deadlines for receipt of a membership appli-cation: March 1 , July 1 , and October 1 of each year. TheMembership Committee will review all complete applications foractive membership that have been received by these deadlinesand will submit recommendations on each candidate to the Boardof Directors which formally elects all members. The same pro-cedure is followed by the Special Memberships Committee whichreceives applications for corresponding membership. Candidateswill be notified according to the following schedule:
Receipt of Applicationin AACR Office Notification of Candidate
March 1 MayJuly 1 SeptemberOctober 1 December
A complete application consists of the following material:
1 . 6 copies of the form on the opposite side of this page,with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitaeand bibliography.
3. 5 copies of a letter of recommendation from a nominatorwho is an active, emeritus, or honorary member of theAACR (at least one copy must be a signed, original letter).This letter should describe the candidate’s achievementsin laboratory research, clinical investigations, or epidemi-ological research, and it should affirm that this researchadheres to accepted ethical standards.-OR-The nomi-nator may supply the responses requested at the bottomof the application form in the section entitled “STATE-MENT OF SUPPORT” (at least one copy of the form mustbe the signed original).
4. 5 copies of a letter of recommendation as described inItem 3. above from a seconder who is an active, emeritus,or honorary member of the AACR (at least one copy mustbe a signed, original letter).-OR--The seconder maysupply the responses requested at the bottom of theapplication form in the section entitled “STATEMENT OFSUPPORT” (at least one copy of the form must be thesigned original).
5. 5 reprints of each of two publications on which the candi-date appears as author.
All material should be collated into five complete sets with theoriginal application form as a covering document and sent to theaddress given below. Questions regarding procedures for mem-bership application may also be directed to thefollowing address:
American Association for Cancer ResearchPublic Ledger Building
Suite 8166th & Chestnut StreetsPhiladelphia, PA 19106
215/440-9300
RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilitiesof membership in the AACR. Active members must pay annualdues, a major portion of which is designated for a subscriptionto at least one of the AACR’s publications. Newly elected mem-bers of the AACR who have already purchased subscriptions toCancer Research or Cell Growth & Differentiation at the higher,nonmember rate will receive reimbursement of the unused por-tion of those subscriptions once their first year’s membershipdues are paid in full.
All corresponding members elected after May 23, 1 985, arerequired to pay an annual assessment in lieu of dues. Thisassessment, which is equivalent to that portion of the regulardues that pertains to support of activities other than publications,is imposed to defray the cost of sending AACR publications tomembers outside the Americas. Corresponding members may,if they wish, subscribe to Cancer Research or Cell Growth &Differentiation at the reduced member rate.
Applicants elected in May will be responsible for payment ofthat year’s dues; applicants elected in September and Decemberwill pay dues in the following year. Applicants elected in May andSeptember will be eligible to sponsor an abstract for the nextannual meeting. Every effort will be made to afford the sameopportunity to applicants elected in December.
Margaret FotiExecutive Director
CANDIDATE NOMINATED BY:.(Please type or print)
CANDIDATE SECONDED BY:.
STATEMENT OF SUPPORT (in place of letters of recommendation)Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:
(Please type or print)
(This form may be reproduced.) 1200
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building
Suite 8166th & Chestnut StreetsPhiladelphia, PA 19106
APPLICATION FOR MEMBERSHIP
CATEGORY OF MEMBERSHIP: 0 Active 0 Corresponding
NAME OF CANDIDATE: ____PRESENT POSITION/TITLE:INSTITUTIONAL AFFILIATION:IMQTITI rnr�MAI �flflQ�Q.
DATE OF BIRTH:
(City)TELEPHONE NUMBER:
FAX NUMBER: ______
(State/Province) (Country) (Postal Code)
PRIMARY FIELD OF RESEARCH (Please check only one):Biochemistry and Biophysics Biostatistics
____Cellular Biology and Genetics ____Clinical Investigations
Epidemiology Immunology
____ Preclinical Pharmacology and Experimental Therapeutics
Virology Other: __________
ACADEMIC DEGREES (Including where and when granted)
CaranogenesisEndocrinology
___Molecular Biology and Genetics
(P�ase specify)
EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)
PUBLICATIONS (Reprints of two articles on which the candidate appears as an author must accompany this application. For thesetwo articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts.)
How long has the candidate worked in the field of cancerresearch? _ yearsWill the candidate make a long-term contribution to cancerresearch? Yes NoDoes the candidate’s research adhere to accepted ethical stand-ards? Yes No
I therefore recommend this candidate for membership in theAmerican Association for Cancer Research.
How long has the candidate worked in the field of cancerresearch? _ yearsWill the candidate make a long-term contribution to cancerresearch? Yes NoDoes the candidate’s research adhere to accepted ethical stand-ards? Yes No
I therefore recommend this candidate for membership in theAmerican Association for Cancer Research.
Signature of nominator Date Signature of seconder Date
See Guidelines for Application on the reverse side of this form for further instructions.
“ Nominators must be active, emeritus, or honorary members of the AACR.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP
QUALIFICATIONS FOR MEMBERSHIP
Associate membership is open to graduate students. medicalstudents. postdoctoral fellows. and physicians in training who live in
the Americas and who are following a course of study or who areworking in a research program relevantto cancer.
BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scien-tific society consisting of laboratory and clinical cancer research-ers, was founded in 1907 “to bring together active investigators ofthe cancer problem for presentation and discussion of new on sig-nificant observations; and to foster research in cancer and otherphenomena of growth.” Associate members ofthe AACR enjoy the
following benefits:
1 . the privilege ofsponsoning an abstnactfor presentation at theAACR annual meeting provided that (a) the associate mem-ben is the presenter ofthe abstract and (b) an active memberin good standing ofthe AACR also signs the abstract in sup-
port ofthe work (In this instance, the active member who co-signs the abstract does not lose his or her own sponsorshipprivilege.);
2. an advance copy of the Program and (if one has been pun-chased by the associate member) the Proceedings of theAmerican Association for Cancer Research which containsabstracts ofall papers being presented at each annual meet-ing;
3. the privilege of registering for the annual meeting at the lowstudent rate (This rate is otherwise available only to predoc�tonal students.);
4. preferred access to the AACR Employment Register;5. an optional subscription to the journal Cancer Research at
the reduced member rate;6. subscriptions to any future AACR journals at reduced mem-
ben rates;7. early notification of events in the AACR’s new series of small
scientific meetings on timely scientific topics;8. the receipt of AACR newsletters, meeting announcements,
and an up-to-date membership directory; and9. the facilitation of informal scientific exchange with leading
researchers in the cancer field.
PROCEDURES FOR APPLICATION
Persons wishingto applyfor associate membership must use the
official application form on the reverse side of these instructions.Each candidate for associate membership must be nominated byan active member in good standing ofthe AACR. Three completedcopies ofthefonm should be submitted; at least one ofthese copiesmust carry the original signatures of both the candidate and theactive member nominator. The application form may be submitted
tothe Association Office at anytime. After review ofapplications forassociate membership, the Executive Director will notify candi-dates oftheir election on deferral within one month of the receipt ofthe application form. A check in the amount of $20, which nepre-sents one year’s dues payment, must accompany the application.This fee will be refunded to any candidate deemed to be ineligiblefor associate membership. Checks should be in U.S. currency,made payable to AACR, Inc., and drawn on a U.S. bank. Send thethree copies ofthe application form and the $20 dues payment to:
American Association for Cancer ResearchPublic Ledger Building
Suite 8166th & Chestnut StreetsPhiladelphia, PA 19106
215/440-9300
RESPONSIBILITIES OF MEMBERSHIP
Associate members must pay annual dues in an amount to bedetermined by the AACR Board of Directors. Dues for 1 991 havebeen set at $20 per year. If an application is submitted by August31 , the accompanying dues payment will be credited to thecurrent year. Candidates submitting applications between Sep-tember 1 and December 31 may indicate whether they wish theirdues payments credited to the current or forthcoming year.Candidates should be aware, however, that associate membersmay sponsor an abstract for the annual meeting only if their duesfor the current year are paid. For example, an associate membersubmitting an abstract in December 1 990 for the forthcomingannual meeting must have paid dues for 1990. Any newly electedassociate members of AACR who have already purchased sub-scriptions to Cancer Research at the higher, nonmember ratewill receive a refund for the unused portion of that subscriptionupon receipt of their payment for a member’s subscription.
Each Fall the AACR will send to current associate membersan invoice for dues for the forthcoming year. Payment of thisinvoice must be accompanied by a statement signed by theassociate member’s current registrar, dean, or department head,verifying the member’s current academic status. The Associa-tion’s By-Laws state that dues are payable for each year inadvance on or before January 1 of that year. An individual maybe an associate member for a maximum of five years. Each yearin which an individual pays dues will count as one full year ofassociate membership. Thus, an associate member who paysdues for 1 990 may retain associate membership until December31 , 1 994. The Board of Directors may terminate the membershipof an associate member whose dues are in arrears for two years.
Margaret Foti,Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.Public Ledger Building
Suite 8166th & Chestnut StreetsPhiladelphia, PA 19106
APPLICATION FOR ASSOCIATE MEMBERSHIP
NAME OF CANDIDATE: ____________________________________ DATE OF BIRTH: _______INSTITUTIONAL AFFILIATION: ______________________________________________________
INSTITUTIONAL ADDRESS:
(City) (State/Province) (Postal Code) (Country)TELEPHONE NUMBER: ______________________
FAX NUMBER: ___________________________
PRESENTACADEM1CSTATUS/TITLE:(Pleasecheckonlyone):____Graduate Student ____Medical Student
Physician in Training Postdoctoral Fellow
PRIMARYFIELDOFRESEARCH(Pleasecheckonlyone):
Biochemistry and Biophysics Biostatistics Carcinogenesis
____Cellular Biology and Genetics ____Clinical investigations Endocrinology
-� Epklemiology Immunology Molecular Biology and Genetics____Preclinical Pharmacology and Experimental Therapeutics
Virology Other: ________________________________________________(Please specify)
ACADEMIC DEGREES(Please indicate degree(s)acquired to date along with the name ofthe academic institution and date of receipt.Provide information on degree currently being sought and the anticipated date of completion of this degree program.)
RELEVANTRESEARCHEXPERIENCENOTRELATEDTOCOURSEWORK(Pieaselistmostrecentfirst.)
PUBLICATIONS (List the authors, title, journal, volume, indusive pages, and year of any article in a peer-reviewed journal on which the
candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)
CANDIDATE NOMINATED BY: ______________________________________________________________(Please type or print name of AACR active member in good standing.)
SIGNATURESI hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverseside of this form, and I understand the Privileges and responsibilities of this class of membership. I certify that the statements on thisapplication are true.
Signature of Candidate: ___________________________________________________ __________________
I recommend this candidate forassociate membership Ifl the American AssociationforCancer Research. To the best ofmy knowledge,the candidate is qualified for this dass of membership, and the statements on this application are true.
�.gnature or I’JOtflIflaIOC ___________________________________________________ Date: __________________
Submit three copies of this form. At least one copy must cont�n the original signatures of the candidate and the nominator. Enclose acheck for $20 � U.S. funds made payable to MCR, Inc. and drawn on a U.S. bank. check one of the f010wing boxes on’y if this form �sbeing submitted between September 1 and December 31:
The enclosed dues payment should be applied to the
0 current 0 forthcoming calendar year.
(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1 , but the candidate willnot be eligible to sponsor an abstract for presentation at the annual meeting in May of that year.) See Guidelines forApplication on the reverse side of this form for further instructions.
(This form may be reproduced.) i 200
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Late applications will be accepted on a space-available basis.
Memlirane Transpoptin MultidrugResistance,Development,and Disease
(co-sponsored by the National Cancer Institute of Canada)
March 10-14, 1991Banif Centre, Banif, Alberta, Canada
CONFERENCE COCHAIRPERSONS
SUSAN B. HORWITZ / Bronx, NY VICTOR UNG / Toronto, Ontaho, canada
PROGRAM COMMIUEE
GIOVANNA F.4.. AMES / Berkeley, CA CAROL E. CASS / Edmonton, Alberta, CanadaANNAMARIACASAZZA / WaHingf�d, CT PHIUPPE GROS / MOntreal,Quebec, Canada
JOHNRIORDAN / Toronto, Ontario, Canada
SCIENTIFIC PROGRAM
TI. Fuit�’s Sf Msdlcal GelisticsVICTOR LING / Toronto, CanadaLOUIS SIMINOVJTOI / Toronto, Canada
PIIsspNryIatIN Slid Sl�uaIIPaIuSIUCtIN
I. BERNARD WEINSTEIN / New York, NY
DAViD L GARBERS / Nashville, TNRANDALLR.REED/ Baltimore, MD
MsmIraN P�ps sal clausis
W1WAM 1. BECK / Memphis, TNWIWAM *� CATIERALL / Seatfie, WAHARVEY F. LODISH / Cambridge, MAREINHART A. F. REITHMEIER / Toronto, Canada
MuItIlru� R�staucs
SUSAN B. HORWITZ / Bronx, NYIGOR B� RONINSON / Ct�cago, ILTAKASHI TSURUO / Tokyo, JapanMICHAEL N. GOT�ESMAN / Bethesda, MDBRUCE A. �HABNER / Bethesda, MD
Information and Application FormsAmerican Assodation for Cancer ResearchPublic Ledger Building, Suite 816Sixth and Chestnut StreetsPhiladelphia, PA 19106215-440-9300 215-440-9313 (FAX)
Ills Cystic Fl�rssIs Clue aid Its
RICHARD BOUf�HER / Chapel Hifi, NCLAP.CHEE TSUI / Toronto,CanadaMICHAEL J. WELSH / Iowa City, IAJOHN R. RIORDAN / Toronto, Canada
P-GIycsprsLs� r=s::�s aNDsvs:::;:=ut
PHIUPPE GROS / Montreal, CanadaPIET BORST / Amsterdam, NethedandsJEREMY THORNER / Berkeley, CAJAMES M. cROOP / Boston, MAALAN COWMAN / M�boume, Australia
MstaNllts aN IWU TPaispsrt
ALAN R. P. PATERSON / Edmonton, CanadaCAROL E. CASS / Edmonton, CanadaI DAVIDGOLDMAN/ Richmond, VASTEPHENB. HOWELL/ La Jolla, CASHIMON SCHULDINER / Jerusalem, Israel
Psri�ass Systsms Is Bactsrla aN
ERNEST N. WRIGHT / Los Angeles, CAGIOVANNA F.-L AMES / Berkeley, CAH. RONALD KABACK / Los Angeles, CA
Ap�IcafIon Deadline:December 3, 1990
Late applications will be accepted on a space-available basis.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Developmental Genetics of clilklliood CancerFebruary8-11, 1991
Catamaran Resort Hotel, San Diego, California
Sup�ed by a Generous Grant fromThe General Motors Cancer Research Foundation
CONFERENCE CHAIRPERSON
ALFRED G. KNUDSON, JR./Philadelphia, PA
PROGRAM COMMITTEE
GARRE1T N. BROOEUR/St. Louis, MOWEBSTER K. CAVENEE/MOntreal, P0, Canada
STEPHEN H. FRlEND/�hadestown, MAGEORGEF. VANDE WOUDE/Frederick, MD
SCIENTIFIC PROGRAM
kiyNts MlrsssALFRED a a�uoso�i, JR./Philadelphia, PA
RI,uIat� St tips cii cycisIRA HERSkOWITZJSan Francisco, CALELAND H. HARTWELLISeatIIe, WAGEORGEF. VANDE WOUDE/Frederick, MD1EAN V. J. WANG/La Jola, CA
ciucspts 51 Isvslspmsut ad Pafisru
SERGEI SOKOL/Cambridge, MAANTHONY P. MAHOWALD/�cago, ILLEWIS WOLPERT/LOndOn, EnglandH. ROBERT H0RVrrz/Cambridge, MA
Dsvslsp#{149}sutalT�srs 51 Mss:�
WEBSTER K. CAVENEE/MOntreel, P0, CanadaERIC OLSEN/Houston, TXDAViD HOUSMAN/Cambridge, MASTEPHEN IL FREND/c�hedestcmn, MA
1�srs 51 thu Isrvsus systs.BERND R. SEIZINGER/Boston, MAGARRETI’ N. BROOEUR/St. Louis, MOMAR11 A. ISRAEL/San Francisco, CA
#{149}svslsps.utlGsustlcs SIks.�� MaN�NCARLO M. cRocE/Ptladelphia, PAJOHN GROFFEN/LOS Angeles, CAHITOSHI SAKANO/Berkeley, CA
�naffon � A� FormsAmerican Association forCancer ResearchPublicLedger Bldg., Suite 816Sixth and Chestnut StreetsPhiladelphia, PA 19106215-440-9300 215-440-9313 (FAX) Nov#{149}mbsv12, 1990
